不用本金就能赚钱的方法

来宝网Logo

热门词:生物显微镜 水质分析仪 微波消解 荧光定量PCR 电化学工作站 生物安全柜

现在位置不用本金就能赚钱的方法>技术资料不用本金就能赚钱的方法>行业动态>新品动态>Sygnis 的DNA聚合酶Qualiphi在美国获得专利

Sygnis 的DNA聚合酶Qualiphi在美国获得专利

Sygnis2013年5月18日 14:50 点击:1384

Sygnis

 SYGNIS制药公司的旗舰产品Qualiphi日前被美国专利商标局授予专利,Qualiphi是一个可用于完整DNA扩增的聚合酶,是长DNA片段和全基因组扩增的主要工具之一。
  Qualiphi提供比市场上同类产品更强的性能,更少的耗时,更佳的灵敏度,其开发者SYGNIS使DNA的扩增浓度低至单细胞中可提取的,这使得癌症和其他研究大大简化。
  SYGNIS的首席执行官Pilar de la Huerta表示:Qualiphi对于DNA扩增的低浓度需求在当今个性化医疗的背景下极具优势,我们预计Qualiphi会成为相关市场必不可少的工具。
  DNA扩增市场近年来有显著增长,全基因组扩增的聚合酶蛋白市场也保持着高增长率。
  2012年,SYGNIS公司全球独家授予Qiagen公司Qualiphi的商品化许可权和转授许可权。

SYGNIS GRANTED US PATENT FOR QUALIPHI®, THE NEXT GENERATION DNA AMPLIFICATION TOOL

 

NEW PATENT OPENS SYGNIS AND QUALIPHI® IN A LEADING POSITION IN A €70 MILLION GLOBAL MARKET.


 

    • QUALIPHI® is a DNA polymerase which has demonstrated the potential to improve complete DNA amplification from minimal concentrations

    • Polymerase proteins are essential in the research and analysis or modification of DNA

    • QUALIPHI® reduces reaction time to 2 hours

    • Currently, the global DNA amplification market is estimated at €70 million, with the US the largest market.
       


Madrid/Heidelberg, 23 April 2013
 – The biotech company SYGNIS Pharma AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) has been granted a patent by the USPTO (US patent and Trademark office) for its flagship product, QUALIPHI® the polymerase for complete DNA amplification. Polymerase proteins are the main tool for amplifying long DNA fragments and whole genomes, and are a basic need for research involving the analysis and modification of DNA. 

QUALIPHI® is an upgraded version of the Phi 29 DNA polymerase used in isothermal amplification which provides enhanced properties compared to similar polymerase proteins on the market. Being less time-consuming and having highly superior performance characteristics, the method developed by SYGNIS enables DNA amplification from concentrations as low as those found in a single cell. This is extremely useful in cancer research, and many other applications.

“Certainly, the need for amplification of nucleic acids from minimal concentrations as present in single cell applications will be a critical issue in the coming era of personalised medicine and NGS. We expect QUALIPHI® to become an essential tool for the DNA amplification needed in these markets”, said SYGNIS’ CEO, Pilar de la Huerta. 

With the significant growth in the field of DNA amplifications used in sequencing and personalised medicine, the market of whole genome amplification with polymerase proteins is expected to grow at over 20% per annum over the next few years. Current estimates indicate that the size of the global isothermal DNA market alone is approximately €70 million, with the US as the leading market for QUALIPHI®.

In 2012, SYGNIS granted an exclusive global licence to QIAGEN, including sublicensing rights, for the commercialization of QUALIPHI® in the DNA amplification market. QIAGEN is a global leader in sample and assay technologies in research and molecular diagnostics.

 

(来源: Sygnis )


全年征稿 / 资讯合作

联系邮箱:kefu@strauss-usa.com不用本金就能赚钱的方法

BANQUANYUMIANZESHENGMING

  • 凡本网注明“来源:来宝网”的所有作品,版权均属于来宝网,转载请必须注明来宝网, http://strauss-usa.com,违反者本网将追究相关法律责任。
  • 本网转载并注明自其它来源的作品,目的在于传递更多信息,并不代表本网赞同其观点或证实其内容的真实性,不承担此类作品侵权行为的直接责任及连带责任。其他媒体、网站或个人从本网转载时,必须保留本网注明的作品来源,并自负版权等法律责任。
  • 如涉及作品内容、版权等问题,请在作品发表之日起一周内与本网联系,否则视为放弃相关权利。


湖南快乐十分 湖南快乐十分 福建快3走势图0 福建快3走势图 河南快3走势图 河南快3走势图 广东11选5开奖结果 福建11选5走势图